Peter Vitins active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Axalbion SA | Director/Board Member | - | - |
Axalbion Therapeutics Ltd.
 Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Director/Board Member | - | - |
Career history of Peter Vitins
Statistics
International
| Switzerland | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 2 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
| Axalbion SA | |
Axalbion Therapeutics Ltd.
Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Health Technology |
- Stock Market
- Insiders
- Peter Vitins
- Experience
